Coya Therapeutics founder Howard Berman steps down as Executive Chairman; Mark Pavao appointed independent director

Coya Therapeutics, Inc.

Howard Berman resigned as Executive Chairman and Board member effective April 1, 2026; part of planned CEO transition initiated November 2024.
Separation agreement includes prorated 2026 bonus at 100% target, COBRA coverage through March 2027, and continued vesting of stock options for 12 months.
Mark H. Pavao appointed as independent Class III director, term expiring at 2028 annual meeting; granted option for 10,000 shares vesting in one year.
Pavao brings 30+ years of biopharma commercial experience, including roles at Bristol-Myers Squibb and R-Pharm US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.